Comparative Pharmacology
Head-to-head clinical analysis: POLYSPORIN versus VUSION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLYSPORIN versus VUSION.
POLYSPORIN vs VUSION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Polysporin is a combination of polymyxin B and bacitracin. Polymyxin B disrupts bacterial cell membrane by binding to lipopolysaccharides, increasing permeability. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier in peptidoglycan synthesis.
Antifungal; inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell membrane synthesis.
Apply a thin layer topically to the affected area 1 to 3 times daily. If using the ointment, cover with a sterile bandage if desired.
Apply a thin layer to the affected area twice daily (morning and evening) for 7 days. Topical use only.
None Documented
None Documented
Polymyxin B: 6–7 hours (impaired renal function: prolonged). Bacitracin: 1.5 hours (topical; not systemically absorbed).
Terminal elimination half-life is approximately 36 hours, reflecting prolonged exposure in stratum corneum and hair follicles; systemic half-life is negligible due to minimal percutaneous absorption.
Polysporin (polymyxin B/bacitracin) ophthalmic/otic/topical: Minimal systemic absorption. Renal elimination for absorbed fraction: <1% of dose.
Primarily eliminated via biliary/fecal route; minimal renal excretion (<5% unchanged). Approximately 80% of the absorbed dose appears in feces as unchanged drug and metabolites.
Category C
Category C
Topical Antibiotic
Topical Antibiotic